GLP‑1 users: new costs

People taking the new weight-loss shots are finding out the prescription is only the first bill. Business Insider reported this week that analysts now peg the add-on spending at roughly $700 to $1,000 a month for things like protein supplements, trainers, skin treatments, and replacement wardrobes. (businessinsider.com) That extra spending sits on top of a drug market that is already enormous. Eli Lilly said in February 2026 that its two glucagon-like peptide 1 drugs, Mounjaro and Zepbound, brought in more than $11 billion in combined quarterly revenue, which shows how many patients are now in the system before the side industries even get counted. (intellectia.ai) The drugs work by cutting appetite, so users often eat less volume and start paying closer attention to what each meal contains. Today.com reported on April 11, 2026 that a new study found many glucagon-like peptide 1 users were falling short on protein, which helps explain why shakes, bars, and diet coaching are turning into recurring purchases. (today.com) That has opened a lane for food brands to sell “support” instead of just snacks. Atkins announced a campaign in January 2026 built around high-protein shakes and bars for glucagon-like peptide 1 users, citing research on digestive issues and muscle support during weight loss. (intellectia.ai) Clothing is becoming one of the clearest second-order costs because bodies can change faster than closets. CivicScience said in February 2025 that glucagon-like peptide 1 users expected to spend more on clothing and groceries, and CNBC reported on April 9, 2026 that Bernstein sees up to $13 billion a year in extra apparel demand tied to these drugs. (civicscience.com) (cnbc.com) The likely winners are not luxury labels first. Bernstein told CNBC that off-price chains like T.J. Maxx, big-box stores like Walmart and Target, and fit-flexible services like Stitch Fix and Rent the Runway could benefit because people changing sizes often want cheaper or temporary replacements before buying a whole new closet. (cnbc.com) Fitness companies are chasing the same customer for a different reason. Business Insider said trainers and gyms are selling muscle-preservation plans to users who are losing weight quickly, because rapid weight loss can also mean losing strength if exercise and protein do not keep up. (businessinsider.com) (today.com) Even the “drug cost” itself is getting more complicated, which makes the side spending easier to miss. Eli Lilly’s official Zepbound savings page says eligible self-pay patients can start at $299 a month, while Novo Nordisk’s current Wegovy offers include some doses at $149 to $199 a month through its pharmacy program, so the medicine can look cheaper upfront even as the total monthly lifestyle bill keeps climbing. (lilly.com) (wegovy.com) At the same time, one older pressure valve is shrinking. The Food and Drug Administration said in February 2025 that the semaglutide injection shortage was resolved, and that has tightened the path for many compounded copies that some patients had used as lower-cost alternatives. (fda.gov) So the new bill for a glucagon-like peptide 1 user is starting to look less like a single pharmacy receipt and more like a wedding budget with surprise line items. The shot may be the reason the spending starts, but the money is increasingly landing at protein brands, gyms, med-spas, and clothing racks that sit far outside the pharmacy counter. (businessinsider.com) (circana.com)